Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NDV-3A Vaccine for Recurrent Vulvovaginal Candidiasis
NCT01926028Phase 2Completed
- Sponsor
- NovaDigm Therapeutics
- Start
- Jul 2013
- Primary completion
- May 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of NDV-3 vaccine in recurrent vulvovaginal candidiasis (RVVC), sponsored by NovaDigm Therapeutics. Started Jul 2013; status: completed.
02
Drugs
NDV-3 vaccine
03
Conditions
recurrent vulvovaginal candidiasis (RVVC)
Beyond the preview
Go deeper on NCT01926028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01926028.